Simon Quick Advisors LLC Sells 21,237 Shares of Pfizer Inc. $PFE

Simon Quick Advisors LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 64.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,569 shares of the biopharmaceutical company’s stock after selling 21,237 shares during the period. Simon Quick Advisors LLC’s holdings in Pfizer were worth $295,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of PFE. Fiduciary Alliance LLC lifted its stake in shares of Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after buying an additional 46,043 shares in the last quarter. Vista Investment Partners LLC increased its stake in Pfizer by 236.1% in the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after buying an additional 48,900 shares in the last quarter. Westbourne Investments Inc. bought a new stake in Pfizer during the first quarter valued at about $2,411,000. Generali Investments CEE investicni spolecnost a.s. lifted its position in shares of Pfizer by 76.4% in the third quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after acquiring an additional 47,319 shares in the last quarter. Finally, Bourne Lent Asset Management Inc. boosted its stake in shares of Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after acquiring an additional 18,200 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: BMO Capital reaffirmed an Outperform rating and a $30 price target, citing Pfizer’s cost controls and a cautious-but-manageable 2026 outlook — a clear vote of confidence for investors focused on valuation and income. BMO reaffirmation
• Positive Sentiment: Multiple bullish analyst/publication pieces argue Pfizer is undervalued and that its pipeline plus deal-making (Seagen, recent obesity-related buys) position it to recover over time — supporting a value-oriented rally. See Fool’s take on medium-term upside. 2 Predictions for Pfizer in 2026
• Positive Sentiment: Analysts at Zacks raised certain near-term quarterly EPS estimates (Q2 2026/Q2 2027), which can help sentiment around upcoming reports and show some upside to consensus in select periods.
• Neutral Sentiment: In-depth pieces (Seeking Alpha, Yahoo Finance) frame 2026 as a “reset” year: higher R&D and acquisition-driven repositioning (notably the Metsera deal) should strengthen Pfizer’s obesity and oncology lineup, but benefits may take time to show. Pfizer 2026: The Reset Year Why Wall Street Gave Up on Pfizer
• Neutral Sentiment: Market commentary reiterates Pfizer’s cheap forward valuation versus peers and highlights that recent M&A (Seagen, Metsera) is beginning to add revenue and late‑stage assets — a longer‑term positive but not immediate earnings relief.
• Negative Sentiment: Pfizer disclosed a death in a long‑term Hympavzi study after a thrombotic stroke — a safety event that could weigh on that program’s outlook and near‑term sentiment. Hympavzi study death
• Negative Sentiment: Analyst estimate trims and management comments point to earnings pressure from the post‑COVID revenue decline and dilution from acquisitions; Zacks trimmed a Q4 EPS estimate — reinforcing near‑term earnings uncertainty.

Pfizer Price Performance

PFE stock opened at $25.17 on Monday. The company has a fifty day simple moving average of $25.18 and a two-hundred day simple moving average of $24.92. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $143.13 billion, a P/E ratio of 14.64 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. UBS Group reaffirmed a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Morgan Stanley lowered their target price on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.06.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.